BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,114,570 | -16.3% | 192,663 | +0.3% | 0.27% | -12.0% |
| Q2 2023 | $15,675,654 | +12.9% | 192,033 | +2.6% | 0.31% | +11.2% |
| Q1 2023 | $13,890,371 | +165.4% | 187,227 | +196.5% | 0.28% | +161.3% |
| Q4 2022 | $5,233,458 | +18.8% | 63,145 | +306.9% | 0.11% | +12.8% |
| Q3 2022 | $4,407,000 | -30.2% | 15,517 | -14.8% | 0.09% | -25.4% |
| Q2 2022 | $6,314,000 | -23.6% | 18,214 | -4.6% | 0.13% | -7.4% |
| Q1 2022 | $8,268,000 | -18.1% | 19,092 | -2.2% | 0.14% | -9.9% |
| Q4 2021 | $10,096,000 | +5.8% | 19,515 | -0.9% | 0.15% | +3.4% |
| Q3 2021 | $9,539,000 | +2.4% | 19,685 | -4.8% | 0.15% | +4.3% |
| Q2 2021 | $9,314,000 | +17.9% | 20,685 | 0.0% | 0.14% | +10.2% |
| Q1 2021 | $7,900,000 | +19.9% | 20,685 | -0.3% | 0.13% | +13.4% |
| Q4 2020 | $6,589,000 | -49.8% | 20,750 | -60.8% | 0.11% | -56.4% |
| Q3 2020 | $13,126,000 | -9.9% | 52,985 | -4.0% | 0.26% | -12.6% |
| Q2 2020 | $14,576,000 | -58.5% | 55,199 | -70.2% | 0.29% | -64.7% |
| Q1 2020 | $35,131,000 | -19.7% | 185,272 | -7.0% | 0.83% | +7.9% |
| Q4 2019 | $43,739,000 | +14.5% | 199,258 | +2.0% | 0.77% | +11.2% |
| Q3 2019 | $38,210,000 | -11.1% | 195,278 | -5.3% | 0.70% | -8.3% |
| Q2 2019 | $42,995,000 | -14.6% | 206,219 | -18.7% | 0.76% | -16.2% |
| Q1 2019 | $50,361,000 | +35.6% | 253,644 | -1.1% | 0.90% | +22.0% |
| Q4 2018 | $37,128,000 | -34.7% | 256,552 | -7.8% | 0.74% | -17.8% |
| Q3 2018 | $56,818,000 | +195.3% | 278,368 | +114.0% | 0.90% | +179.6% |
| Q2 2018 | $19,244,000 | +5.3% | 130,071 | +7.5% | 0.32% | +3.2% |
| Q1 2018 | $18,278,000 | +5.4% | 121,013 | -9.6% | 0.31% | +6.1% |
| Q4 2017 | $17,334,000 | -5.5% | 133,798 | -11.9% | 0.30% | -7.8% |
| Q3 2017 | $18,351,000 | -21.2% | 151,803 | -23.4% | 0.32% | -21.6% |
| Q2 2017 | $23,295,000 | +9.0% | 198,253 | -5.7% | 0.41% | +7.1% |
| Q1 2017 | $21,378,000 | +9.7% | 210,308 | +11.0% | 0.38% | +4.4% |
| Q4 2016 | $19,480,000 | -27.4% | 189,440 | -22.6% | 0.36% | -24.3% |
| Q3 2016 | $26,818,000 | -9.1% | 244,910 | -6.4% | 0.48% | -9.7% |
| Q2 2016 | $29,502,000 | -8.5% | 261,615 | -23.3% | 0.53% | -3.6% |
| Q1 2016 | $32,248,000 | +4.2% | 341,180 | -0.8% | 0.55% | +9.3% |
| Q4 2015 | $30,946,000 | -25.0% | 343,845 | -23.0% | 0.51% | -22.7% |
| Q3 2015 | $41,282,000 | -21.1% | 446,485 | -16.0% | 0.66% | -7.5% |
| Q2 2015 | $52,343,000 | -31.4% | 531,565 | -30.1% | 0.71% | -23.1% |
| Q1 2015 | $76,290,000 | +7.4% | 760,690 | -1.1% | 0.92% | +11.2% |
| Q4 2014 | $71,037,000 | – | 768,796 | – | 0.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |